|
1.
|
Huang Y, Jin H, Liu Y, et al: FSH inhibits
ovarian cancer cell apoptosis by up-regulating survivin and
down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Gu G, Yuan J, Wills M and Kasper S:
Prostate cancer cells with stem cell characteristics reconstitute
the original human tumor in vivo. Cancer Res. 67:4807–4815. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Karoubi G, Gugger M, Schmid R and Dutly A:
OCT4 expression in human non-small cell lung cancer: implications
for therapeutic intervention. Interact Cardiovasc Thorac Surg.
8:393–397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Atlasi Y, Mowla SJ, Ziaee SA and Bahrami
AR: OCT-4, an embryonic stem cell marker, is highly expressed in
bladder cancer. Int J Cancer. 120:1598–1602. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ezeh UI, Turek PJ, Reijo RA and Clark AT:
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are
expressed in both seminoma and breast carcinoma. Cancer.
104:2255–2265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Shin S, Mitalipova M, Noggle S, et al:
Long-term proliferation of human embryonic stem cell-derived
neuroepithelial cells using defined adherent culture conditions.
Stem Cells. 24:125–138. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Tai MH, Chang CC, Kiupel M, Webster JD,
Olson LK and Trosko JE: Oct4 expression in adult human stem cells:
evidence in support of the stem cell theory of carcinogenesis.
Carcinogenesis. 26:495–502. 2005.PubMed/NCBI
|
|
8.
|
Zhang S, Balch C, Chan MW, et al:
Identification and characterization of ovarian cancer-initiating
cells from primary human tumors. Cancer Res. 68:4311–4320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chiou SH, Wang ML, Chou YT, et al:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Hu T, Liu S, Breiter DR, Wang F, Tang Y
and Sun S: Octamer 4 small interfering RNA results in cancer stem
cell-like cell apoptosis. Cancer Res. 68:6533–6540. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Asselin-Labat ML, Vaillant F, Sheridan JM,
et al: Control of mammary stem cell function by steroid hormone
signalling. Nature. 465:798–802. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Joshi PA, Jackson HW, Beristain AG, et al:
Progesterone induces adult mammary stem cell expansion. Nature.
465:803–807. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Baba T, Convery PA, Matsumura N, et al:
Epigenetic regulation of CD133 and tumorigenicity of
CD133+ ovarian cancer cells. Oncogene. 28:209–218. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Ferrandina G, Bonanno G, Pierelli L, et
al: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J
Gynecol Cancer. 18:506–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Curley MD, Therrien VA, Cummings CL, et
al: CD133 expression defines a tumor initiating cell population in
primary human ovarian cancer. Stem Cells. 27:2875–2883.
2009.PubMed/NCBI
|
|
17.
|
Alvero AB, Chen R, Fu HH, et al: Molecular
phenotyping of human ovarian cancer stem cells unravels the
mechanisms for repair and chemoresistance. Cell Cycle. 8:158–166.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Dou J, Jiang C, Wang J, et al: Using
ABCG2-molecule-expressing side population cells to identify cancer
stem-like cells in a human ovarian cell line. Cell Biol Int.
35:227–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gao Q, Geng L, Kvalheim G, Gaudernack G
and Suo Z: Identification of cancer stem-like side population cells
in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol.
33:175–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Chen X, Zhang Z, Feng Y, et al: Aberrant
survivin expression in endometrial hyperplasia: another mechanism
of progestin resistance. Mod Pathol. 22:699–708. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ji Q, Liu PI, Chen PK and Aoyama C:
Follicle stimulating hormone-induced growth promotion and gene
expression profiles on ovarian surface epithelial cells. Int J
Cancer. 112:803–814. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhang Z, Jia L, Feng Y and Zheng W:
Overexpression of follicle-stimulating hormone receptor facilitates
the development of ovarian epithelial cancer. Cancer Lett.
278:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Liu D, Zhou P, Zhang L, Wu G, Zheng Y and
He F: Differential expression of Oct4 in HPV-positive and
HPV-negative cervical cancer cells is not regulated by DNA
methyltransferase 3A. Tumour Biol. 32:941–950. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Iki K and Pour PM: Expression of Oct4, a
stem cell marker, in the hamster pancreatic cancer model.
Pancreatology. 6:406–413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wang XQ, Ongkeko WM, Chen L, et al:
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver
cancer cells through a potential Oct4-AKT-ATP-binding cassette G2
pathway. Hepatology. 52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Venn A, Watson L, Bruinsma F, Giles G and
Healy D: Risk of cancer after use of fertility drugs with in-vitro
fertilisation. Lancet. 354:1586–1590. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Brekelmans CT: Risk factors and risk
reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol.
15:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tavani A, Ricci E, La Vecchia C, et al:
Influence of menstrual and reproductive factors on ovarian cancer
risk in women with and without family history of breast or ovarian
cancer. Int J Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Riman T, Persson I and Nilsson S: Hormonal
aspects of epithelial ovarian cancer: review of epidemiological
evidence. Clin Endocrinol (Oxf). 49:695–707. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Li Y, Ganta S, Cheng C, Craig R, Ganta RR
and Freeman LC: FSH stimulates ovarian cancer cell growth by action
on growth factor variant receptor. Mol Cell Endocrinol. 267:26–37.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lau MT, Wong AS and Leung PC:
Gonadotropins induce tumor cell migration and invasion by
increasing cyclooxygenases expression and prostaglandin E(2)
production in human ovarian cancer cells. Endocrinology.
151:2985–2993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Choi JH, Choi KC, Auersperg N and Leung
PC: Gonadotropins activate proteolysis and increase invasion
through protein kinase A and phosphatidylinositol 3-kinase pathways
in human epithelial ovarian cancer cells. Cancer Res. 66:3912–3920.
2006. View Article : Google Scholar
|
|
33.
|
Xu H, Wang W, Li C, et al: WWP2 promotes
degradation of transcription factor OCT4 in human embryonic stem
cells. Cell Res. 19:561–573. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Chen T, Du J and Lu G: Cell growth arrest
and apoptosis induced by Oct4 or Nanog knockdown in mouse embryonic
stem cells: a possible role of Trp53. Mol Biol Rep. 39:1855–1861.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Qian X, Xi X and Li L: Nuclear survivin is
associated with malignant potential in epithelial ovarian
carcinoma. Appl Immunohistochem Mol Morphol. 19:126–132. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Zhang Z, Liao H, Chen X, et al:
Luteinizing hormone upregulates survivin and inhibits apoptosis in
ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol.
155:69–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
